Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 1848 word(s) 1848 2021-01-25 04:28:28 |
2 format correct -21 word(s) 1827 2021-01-26 02:59:22 | |
3 move out of the EC Meta information modification 1827 2021-10-11 02:59:38 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Kim, K. Nanomaterials Combined with Bacteriocins. Encyclopedia. Available online: (accessed on 19 June 2024).
Kim K. Nanomaterials Combined with Bacteriocins. Encyclopedia. Available at: Accessed June 19, 2024.
Kim, Kwang-Sun. "Nanomaterials Combined with Bacteriocins" Encyclopedia, (accessed June 19, 2024).
Kim, K. (2021, January 26). Nanomaterials Combined with Bacteriocins. In Encyclopedia.
Kim, Kwang-Sun. "Nanomaterials Combined with Bacteriocins." Encyclopedia. Web. 26 January, 2021.
Nanomaterials Combined with Bacteriocins

Bacteriocins are antimicrobial peptides or proteinaceous materials produced by bacteria against pathogens. These molecules have high efficiency and specificity and are equipped with many properties useful in food-related applications, such as food preservatives and additives, as well as biomedical applications, such as serving as alternatives to current antibacterial, antiviral, anti-cancer, and antibiofilm agents. Despite their advantages as alternative therapeutics over existing strategies, several limitations of bacteriocins, such as the high cost of isolation and purification, narrow spectrum of activity, low stability and solubility, and easy enzymatic degradation, need to be improved. Nanomaterials are promising agents in many biological applications. They are widely used in the conjugation or decoration of bacteriocins to augment the activity of bacterioc-ins or reduce problems related to their use in biomedical applications. Therefore, bacteriocins combined with nanomaterials have emerged as promising molecules that can be used in various biomedical applications.

bacteriocin nanomaterial biomedical applications nanomedicine bacteriocin nanoconjugate

1. Introduction

Bacteriocins are a group of ribosomally synthesized peptides that are secreted extracellularly by various gram-positive and gram-negative bacteria [1], although a majority of bacteriocins reported are produced by the former, especially lactic acid bacteria (LAB) [2][3]. Extensive studies have been carried out on bacteriocins owing to their excellent antibacterial activity, which is closely associated with strain producing species. In addition, bacteriocins have garnered considerable research attention in the field of biomedicine owing to their generally recognized as safe (GRAS) status, and because they are safe for human consumption due to their degradation by gastrointestinal proteases [4]. They are also being modified to improve the antibacterial spectrum. Most of the well-known bacteriocins are produced by gram-positive bacteria, whereas only a few from gram-negative bacteria have been characterized [5]. The activity of these small bacteriocins consisting of cationic molecules (30–60 amino acids) vary throughout the antibacterial spectrum, mainly due to their amphiphilic helices.

Bacteriocins are widely used as natural food preservatives—substances that delay the growth of microorganisms—in the food industry, because they are easily degraded by enzymes produced in the human gastrointestinal tract [4]. The high quality and safety profile of bacteriocins as natural food preservatives is possible without the use of chemical preservatives, which is strictly regulated by governmental agencies, such as the Food and Drug Administration (FDA) in the United States, owing to their safety issues. Generally, bacteriocins can be directly added to food or incorporated into food during cultivation with the help of bacteriocin-producing bacterial strains. More recently, bacteriocins have gained considerable attention in the healthcare industry as antibacterial and anticancer agents [6]. Some bacteriocins, such as nisin, have shown excellent and specific antibacterial activity against multi-drug resistant (MDR) strains of gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) [7]. Moreover, gram-negative bacteria are naturally resistant to the action of bacteriocins produced by gram-positive bacteria, which are widely explored in foods. It is worthy to note that the bacteriocins produced by gram-positive bacteria can be combined with antibacterial nanoparticles to inhibit the growth of gram-negative bacteria such as P. aeruginosa. In this respect, Au-nisin successfully experimented for the bacterial growth inhibition of E. coli and P. aeruginosa [8]. Currently, researchers are investigating the biomedical properties of bacteriocins in several anticancer studies and have reported promising results [9]. Therefore, researchers are highly interested to use bacteriocins as safe materials in biomedical applications.

Despite their promising advantages, bacteriocins have certain limitations that hinder their applications in the field of biomedicine [10]. These limitations include the following: (i) easy degradation by proteolytic enzymes, (ii) constricted antibacterial spectrum, (iii) requirement of high dosage to kill MDR bacteria, (iv) high production cost, and (v) low natural production yield. Based on these limitations, only three FDA-approved bacteriocins (nisin, pediocin, and Micocin®) are available for food preservation and anti-spoilage processes [11]. The optimization of different production conditions, purification methods, and combinations with other antimicrobial agents or antibiotics has been assessed by various studies to overcome the aforementioned shortcomings in ensuring the broad application of bacteriocins in biomedicine. As adjuvant bioactive materials for bacteriocins, nanomaterials seem highly promising to overcome these challenges [12]. The major reasons for the use of nanomaterials can be attributed to their following characteristics: (i) broad antibacterial spectrum, (ii) stability in physiological solution, (iii) high surface area-to-volume ratio, (iv) easy to synthesize with low production cost, and (v) non-toxic nature at low concentrations. Bacteria are unable to generate rapid resistance against nanomaterials owing to their multi-dimensional approach compared to antibiotics, which targets a single cellular component [13]. Therefore, the combination of bacteriocins and nanomaterials offers new tactics to overcome the limitations posed by the sole use of bacteriocins in biomedical applications.

2. Bacteriocin–Nanomaterial Combination

Nanomaterials have been recently used to potentially overcome such limitations [16]. For instance, researchers have already developed bacteriocin–nanomaterial complexes or bacteriocin–nanoconjugates for various biomedical applications of bacteriocins. Multiple advantages for the use of bacteriocin–nanoconjugates have been reported: (i) increased stability for long periods of use, (ii) protection from proteolytic enzyme degradation, and (iii) synergistic activity. The potential applicability of bacteriocin–nanoconjugates with different nanomaterials has been described in following sections.

2.1. Liposomes

Liposomes are spherical vesicles comprising single or multiple phospholipid bilayer membranes [14][15][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43]. They are non-toxic and biodegradable agents as well as suitable encapsulating materials for both hydrophilic and hydrophobic substances. The size scale of liposomes varies from micrometers to nanometers, generated via sonication or functionalization [44]. Nano-sized liposomes—called nano-liposomes—are promising vehicles for the encapsulation and delivery of different bioactive compounds such as enzymes, vitamins, and food additives, as well as the delivery of therapeutic bacteriocins to target cells. Liposome encapsulation protects bacteriocins (Figure 1) from degradation caused by physicochemical environment or protease action [45], susceptibility to which is a major limitation of bacteriocins. Various studies addressing the protection of bacteriocins from protease degradation have been reported [46][47]. Liposome encapsulation also confers other advantages, such as improved stability, reduced doses in therapeutic applications, and enhanced antibacterial spectrum. Taylor et al. [48] showed that liposomes consisting of distearoylphosphatidylcholine (PC) and distearoylphosphatidylglycerol (PG) with trapped nisin can retain approximately 70–90% of the incorporated nisin with high stability under alkaline pH and elevated temperatures (25–75 °C). Similarly, Pinilla et al. [49] showed that nanoliposomes co-encapsulated with nisin and garlic extracts became broad-spectrum antimicrobial agents against L. monocytogenes, Salmonella enteritidis, E. coli, and S. aureus. This expanded antibacterial spectrum has shown that bacteriocin could be modulated to be active on both gram-positive and -negative bacteria. The successful application of liposome-encapsulated bacteriocins depends on appropriate phospholipid bacteriocin combinations, the avoidance of adverse liposome–bacteriocin interactions, and high purity of starting materials. Such liposome-encapsulated bacteriocins have been mainly used as antibacterial substances [49] and have food-related [50] applications.

Figure 1. Schematic representation of bacteriocin encapsulation with liposome for antibacterial activity.

2.2. Chitosan

Chitosan is another type of nanoparticle, which is widely used with bacteriocins in various biomedical applications. Chitosan is an ideal candidate for these applications due to its non-toxic, biocompatible, and biodegradable nature [51]. Moreover, its antibacterial and anticancer activity coupled with its ability to deliver drugs to their targets is well researched [51][52]. Many researchers have used chitosan with bacteriocins to obtain a material showing synergistic antibacterial activity. For instance, Namasivayam et al. [53] reported synergistic antibacterial activity of chitosan–nanoconjugates loaded with bacteriocins against Listeria monocytogenes; the activity levels of these nanoconjugates were higher than those of free bacteriocins. In another study, Alireza Alishahi [54] demonstrated excellent antibacterial activity by chitosan nanoparticles loaded with nisin against E. coli and S. aureus. Moreover, nanocomposite comprised of bacteriocin and chitosan have also been used in food packaging (Figure 2). For example, Divsalar et al. [55] formed a composite film containing chitosan, cellulose, and nisin for use in packaging of ultra-filtered cheese. The composite film showed better food packaging properties than chitosan and cellulose film alone. Similar studies have been conducted using bacteriocin–chitosan nanocomposites for drug delivery [56].

Figure 2. Schematic representation of improved food packaging with bacteriocin.

2.3. Metallic Nanoparticles

Currently, metallic nanoparticles such as zinc, copper, silver, and gold are being studied not only for their antibacterial activity, but also for their different potential biomedical applications [57][58][59][60]. The extensive use of these nanoparticles can be attributed to their large surface area along with their positive charge, which can interact with negatively charged bacterial cell surfaces. Among bacteriocin–metallic nanocomposites, Ag and Au nanoparticles are the most studied materials, showing synergistic effects in biomedical applications. The antibacterial activity of Ag and Au nanoparticles is well reported. Therefore, it is easy to understand the rationale behind the combination of bacteriocins with Ag/Au nanoparticles. This combination will not only enlarge the antibacterial spectrum, but also reduce the toxicity of nanoparticles. In this respect, Sharma et al.  reported enterocin-coated silver nanoparticles, which not only showed broad-spectrum inhibition against various food-borne pathogenic bacteria but also admirable non-toxicity to red blood cells, emphasizing its biocompatible nature. Pandit et al. [61] also reported the antibacterial activity of Ag–nisin nanoconjugates against Listeria monocytogenes, S. aureus, Pseudomonas fluorescens, Aspergillus niger, and Fusarium moniliforme associated with food spoilage. These results reveal the potential uses of bacteriocin–metal nanoconjugates in food packaging. Preet et al. [62] also reported the use of Au nanoparticles in other biomedical applications such as the co-delivery of nisin and doxorubicin to treat murine skin cancer.

2.4. Nanofibers

Nanofiber technology is known for its application in wound care formulations, wherein nanofibers are loaded with antimicrobials and hemostatic agents for wound healing. Bacteriocins can also be loaded with nanofibers for the same purpose. The large surface area, high physical stability, and excellent encapsulation ability along with small pore size have made nanofibers the perfect nanocarriers for target-specific drug delivery [63]. Nanofiber-based bacteriocin–nanoconjugates are used as antibacterial and antiviral substances. In a recent study, Torres et al. [64] explored the efficacy of a subtilosin-loaded poly(vinyl alcohol) (PVOH) nanofiber as an antiviral agent against Herpes simplex virus type 1 (HSV-1). Subtilosin with 200 µg mL-1 showed a remarkable virucidal and antiviral activity against HSV-1, although the mechanistic action has not been elucidated. The PVOH-based subtilosin nanofibers with a width of 278 nm has retained subtilosin’s antibacterial efficacy, increased the loading potential of subtilosin (2.4 mg subtilosin/g of fiber) with loading efficiency of 31.6%, and demonstrated non-toxicity to human epidermal tissues. Electrospinning-based bacteriocin-nanofibers have also been studied as a drug delivery system. For instance, Ahire et al. [65] determined the activity of nisin incorporated into nanofibers prepared from poly(D,L-lactide) (PDLLA) and poly (ethylene oxide) (PEO). This combination has shown enhanced antibiofilm activity against MRSA than that by nisin alone.

2.5. Other Nanoplatforms

Researchers are attempting to use nanoplatforms other than liposomes, chitosan, metallic nanoparticles, or nanofibers to encapsulate or conjugate bacteriocins with nanomaterials. Niaz et al. [66] used bacteriocin-loaded nanovesicles due to their excellent antimicrobial and antibiofilm activities against food-borne pathogens. Similarly, Breukink et al. [67] evaluated the binding of nisin Z to bilayer lipid vesicles. Yadav et al. [68] assessed the interaction between nisin and vesicles synthesized using different phospholipids. Another example of nanoplatforms is solid–lipid nanoparticles (SLN), which have been used to encapsulate bacteriocins for various biomedical applications. Bacteriocin-loaded SLN not only protect bacteriocins from degradation but also extend their antibacterial activity for a long period of time[69]. Phytoglycogen nanoparticles are another type of nanomaterial used to carry bacteriocins to the target site [70].


  1. Cotter, P.D.; Hill, C.; Ross, R.P. Bacteriocins: Developing innate immunity for food. Nat. Rev. Microbiol. 2005, 3, 777–788.
  2. Hassan, M.; Kjos, M.; Nes, I.F.; Diep, D.B.; Lotfipour, F. Natural antimicrobial peptides from bacteria: Characteristics and potential applications to fight against antibiotic resistance. J. Appl. Microbiol. 2012, 113, 723–736.
  3. Klaenhammer, T.R. Bacteriocins of lactic acid bacteria. Biochimie 1988, 70, 337–349.
  4. Silva, C.C.G.; Silva, S.P.M.; Ribeiro, S.C. Application of bacteriocins and protective cultures in dairy food preservation. Front. Microbiol. 2018, 9, 594.
  5. Ansari, A. Bacteriocin from LAB for medical and health applications. In Beneficial Microorganisms in Medical and Health Appli-cations. Microbiology Monographs; Liong, M.T., Ed.; Springer: Cham, Switzerland, 2015; Volume 28, pp. 199–221.
  6. Shin, J.M.; Gwak, J.W.; Kamarajan, P.; Fenno, J.C.; Rickard, A.H.; Kapila, Y.L. Biomedical applications of nisin. J. Appl. Mi-crobiol. 2016, 120, 1449–1465.
  7. Field, D.; O’Connor, R.; Cotter, P.D.; Ross, R.P.; Hill, C. In Vitro activities of nisin and nisin derivatives alone and in combi-nation with antibiotics against Staphylococcus biofilms. Front. Microbiol. 2016, 7, 508.
  8. Vukomanović, M.; Žunič, V.; Kunej, Š.; Jančar, B.; Jeverica, S.; Podlipec, R.; Suvorov, D. Nano-engineering the antimicrobial spectrum of lantibiotics: Activity of nisin against gram negative bacteria. Sci. Rep. 2017, 7, 4324.
  9. Baindara, P.; Korpole, S.; Grover, V. Bacteriocins: Perspective for the development of novel anticancer drugs. Appl. Microbiol. Biotechnol. 2018, 102, 10393–10408.
  10. Fahim, H.A.; Khairalla, A.S.; El-Gendy, A.O. Nanotechnology: A valuable strategy to improve bacteriocin formulations. Front. Microbiol. 2016, 7, 1385.
  11. Radaic, A.; de Jesus, M.B.; Kapila, Y.L. Bacterial anti-microbial peptides and nano-sized drug delivery systems: The state of the art toward improved bacteriocins. J. Control. Release 2020, 321, 100–118.
  12. Naskar, A.; Kim, K.-s. Nanomaterials as delivery vehicles and components of new strategies to combat bacterial infections: Advantages and limitations. Microorganisms 2019, 7, 356.
  13. Naskar, A.; Lee, S.; Lee, Y.; Kim, S.; Kim, K.-s. A new nano-platform of erythromycin combined with Ag nano-particle ZnO nano-structure against methicillin-resistant Staphylococcus aureus. Pharmaceutics 2020, 12, 841.
  14. Micenková, L.; Bosák, J.; Kucera, J.; Hrala, M.; Dolejšová, T.; Šedo, O.; Linke, D.; Fišer, R.; Šmajs, D. Colicin Z, a structurally and functionally novel colicin type that selectively kills enteroinvasive Escherichia coli and Shigella strains. Sci. Rep. 2019, 9, 11127.
  15. Eberhart, L.J.; Deringer, J.R.; Brayton, K.A.; Sawant, A.A.; Besser, T.E.; Call, D.R. Characterization of a novel microcin that kills enterohemorrhagic Escherichia coli O157:H7 and O26. Appl. Environ. Microbiol. 2012, 78, 6592–6599.
  16. Sidhu, P.K.; Nehra, K. Bacteriocin-nanoconjugates as emerging compounds for enhancing antimicrobial activity of bacteri-ocins. J. King Saud Univ. Sci. 2019, 31, 758–767.
  17. Yang, S.C.; Lin, C.H.; Sung, C.T.; Fang, J.Y. Antibacterial activities of bacteriocins: Application in foods and pharmaceuticals. Front Microbiol. 2014, 5, 241.
  18. Li, Q.; Montalban-Lopez, M.; Kuipers, O.P. Increasing the antimicrobial activity of nisin-based Lantibiotics against Gram-Negative pathogens. Appl. Environ. Microbial. 2018, 84, e00052-18.
  19. Weishaupt, R.; Heuberger, L.; Siqueira, G.; Gutt, B.; Zimmermann, T.; Maniura-Weber, K.; Salentinig, S.; Faccio, G. Enhanced antimicrobial activity and structural transitions of a nanofibrillated cellulose-nisin biocomposite suspension. Acs Appl. Mater. Interfaces 2018, 10, 20170–20181.
  20. Holcapkova, P.; Raskova, Z.K.; Hrabalikova, M.; Salakova, A.; Drbohlav, J.; Sedlarik, V. Isolation and thermal stabilization of bacteriocin nisin derived from whey for antimicrobial modifications of polymers. Int. J. Polym. Sci. 2017, 2017, 3072582.
  21. Wang, G. Post-translational modifications of natural antimicrobial peptides and strategies for peptide engineering. Curr. Bio-technol. 2012, 1, 72–79.
  22. Lagedroste, M.; Reiners, J.; Smits, S.H.J.; Schmitt, L. Impact of the nisin modification machinery on the transport kinetics of NisT. Sci. Rep. 2020, 10, 12295.
  23. Peng, X.; Zhu, L.; Wang, Z.; Zhan, X. Enhanced stability of the bactericidal activity of nisin through conjugation with gellan gum. Int. J. Biol. Macromol. 2020, 148, 525–532.
  24. Bagde, P.; Vigneshwaran, N. Improving the stability of bacteriocin extracted from Enterococcus faecium by immobilization onto cellulose nanocrystals. Carbohydr. Polym. 2019, 209, 172–180.
  25. Fahim, H.A.; El Rouby, W.M.A.; El-Gendy, A.O.; Khairalla, A.S.; Naguib, I.A.; Farghali, A.A. Enhancement of the productiv-ity of the potent bacteriocin avicin A and improvement of its stability using nanotechnology approaches. Sci. Rep. 2017, 7, 10604.
  26. Da Silva Malheiros, P.; Daroit, D.J.; Brandelli, A. Food applications of liposome-encapsulated antimicrobial peptides. Trends Food Sci. Technol. 2010, 21, 284–292.
  27. Da Silva Malheiros, P.; Sant’Anna, V.; Utpott, M.; Brandelli, A. Antilisterial activity and stability of nanovesicle-encapsulated antimicrobial peptide P34 in milk. Food Control 2012, 23, 42–47.
  28. Lee, E.H.; Khan, I.; Oh, D.H. Evaluation of the efficacy of nisin-loaded chitosan nanoparticles against foodborne pathogens in orange juice. J. Food Sci. Technol. 2018, 55, 1127–1133.
  29. Salmaso, S.; Elvassore, N.; Bertucco, A.; Lante, A.; Caliceti, P. Nisin-loaded poly-L-lactide nano-particles produced by CO2 anti-solvent precipitation for sustained antimicrobial activity. Int. J. Pharm. 2004, 287, 163–173.
  30. Simons, A.; Alhanout, K.; Duval, R.E. Bacteriocins, antimicrobial peptides from bacterial origin: Overview of their biology and their impact against multidrug-resistant bacteria. Microorganisms 2020, 8, 639.
  31. Mathur, H.; Field, D.; Rea, M.C.; Cotter, P.D.; Hill, C.; Ross, R.P. Bacteriocin-antimicrobial synergy: A medical and food per-spective. Front. Microbiol. 2017, 8, 1205.
  32. Sharma, T.K.; Sapra, M.; Chopra, A.; Sharma, R.; Patil, S.D.; Malik, R.K.; Pathania, R.; Navani, N.K. Interaction of bacteri-ocin-capped slver nanoparticles with food pathogens and their antibacterial effect. Int. J. Green Nanotechnol. 2012, 4, 93–110.
  33. Joo, N.E.; Ritchie, K.; Kamarajan, P.; Miao, D.; Kapila, Y.L. Nisin, an apoptogenic bacteriocin and food preservative, attenu-ates HNSCC tumorigenesis via CHAC1. Cancer Med. 2012, 1, 295–305.
  34. Ray Mohapatra, A.; Jeevaratnam, K. Inhibiting bacterial colonization on catheters: Antibacterial and antibiofilm activities of bacteriocins from Lactobacillus plantarum SJ33. J. Glob. Antimicrob. Resist. 2019, 19, 85–92.
  35. Hegarty, J.W.; Guinane, C.M.; Ross, R.P.; Hill, C.; Cotter, P.D. Bacteriocin production: A relatively unharnessed probiotic trait? F1000Res. 2016, 5, 2587.
  36. Gillor, O.; Etzion, A.; Riley, M.A. The dual role of bacteriocins as anti- and probiotics. Appl. Microbiol. Biotechnol. 2008, 81, 591–606.
  37. Chauhan, A.; Singh, R. Probiotics in aquaculture: A promising emerging alternative approach. Symbiosis 2019, 77, 99–113.
  38. Flynn, J.; Durack, E.; Collins, M.N.; Hudson, S.P. Tuning the strength and swelling of an injectable polysaccharide hydrogel and the subsequent release of a broad spectrum bacteriocin, nisin A. J. Mater. Chem. B. 2020, 8, 4029–4038.
  39. Heunis, T.; Bshena, O.; Klumperman, B.; Dicks, L. Release of bacteriocins from nanofibers prepared with combinations of poly(d,l-lactide) (PDLLA) and poly(ethylene oxide) (PEO). Int. J. Mol. Sci. 2011, 12, 2158–2173.
  40. Woraprayote, W.; Pumpuang, L.; Tosukhowong, A.; Zendo, T.; Sonomoto, K.; Benjakul, S.; Visessanguan, W. Antimicrobial biodegradable food packaging impregnated with Bacteriocin 7293 for control of pathogenic bacteria in pangasius fish fillets. LWT 2018, 89, 427–433.
  41. Bastos Mdo, C.; Coelho, M.L.; Santos, O.C. Resistance to bacteriocins produced by Gram-positive bacteria. Microbiology 2015, 161, 683–700.
  42. Dicks, L.M.T.; van Staden, A.D.P.; Klumperman, B. Bacteriocins and nanotechnology. In Functionalized Nanomaterials for the Management of Microbial Infection; Boukherroub, R.; Szunerits, S.; Drider, D., Eds.; Elsevier: Amsterdam, The Netherlands, 2017; pp. 267–288.
  43. Panahi, Y.; Farshbaf, M.; Mohammadhosseini, M.; Mirahadi, M.; Khalilov, R.; Saghfi, S.; Akbarzadeh, A. Recent advances on liposomal nanoparticles: Synthesis, characterization and biomedical applications. Artif. Cells Nanomed. Biotechnol. 2017, 45, 788–799.
  44. Lujan, H.; Griffin, W.C.; Taube, J.H.; Sayes, C.M. Synthesis and characterization of nanometer-sized liposomes for encapsu-lation and microRNA transfer to breast cancer cells. Int. J. Nanomed. 2019, 14, 5159–5173.
  45. Tsumori, H.; Shimizu, Y.; Nagatoshi, K.; Sakurai, Y.; Yamakami, K. Prospects for liposome-encapsulated nisin in the preven-tion of dental caries. In Interface Oral Health Science 2014; Sasaki, K., Suzuki, O., Takahashi, N., Eds.; Springer, Tokyo, Japan, 2015.
  46. Benech, R.O.; Kheadr, E.E.; Lacroix, C.; Fliss, I. Antibacterial activities of nisin Z encapsulated in liposomes or produced in situ by mixed culture during cheddar cheese ripening. Appl. Environ. Microbiol. 2002, 68, 5607–5619.
  47. Were, L.M.; Bruce, B.; Davidson, P.M.; Weiss, J. Encapsulation of nisin and lysozyme in liposomes enhances efficacy against Listeria monocytogenes. J. Food Prot. 2004, 67, 922–927.
  48. Taylor, T.M.; Gaysinsky, S.; Davidson, P.M.; Bruce, B.D.; Weiss, J. Characterization of antimicrobial-bearing liposomes by ζ-potential, vesicle size, and encapsulation efficiency. Food Biophys. 2007, 2, 1–9.
  49. Pinilla, C.M.B.; Brandelli, A. Antimicrobial activity of nanoliposomes co-encapsulating nisin and garlic extract against Gram-positive and Gram-negative bacteria in milk. Innov. Food Sci. Emerg. Technol. 2016, 36, 287–293.
  50. Bahrami, A.; Delshadi, R.; Jafari, S.M.; Williams, L. Nanoencapsulated nisin: An engineered natural antimicrobial system for the food industry. Trends Food Sci. Technol. 2019, 94, 20–31.
  51. Zhao, D.; Yu, S.; Sun, B.; Gao, S.; Guo, S.; Zhao, K. Biomedical applications of chitosan and its derivative nanoparticles. Pol-ymers 2018, 10, 462.
  52. Ojeda-Hernández, D.D.; Canales-Aguirre, A.A.; Matias-Guiu, J.; Gomez-Pinedo, U.; Mateos-Díaz, J.C. Potential of chitosan and its derivatives for biomedical applications in the central nervous system. Front. Bioeng. Biotechnol. 2020, 8, 389.
  53. Namasivayam, S.K.R.; Krishnappa, S.; Debnath, S.; Jayaprakash, C. Biocompatible chitosan nanoparticles incorporated bac-teriocin (CSNps-B) preparation for the controlled release and improved anti-bacterial activity against food borne pathogenic bacteria List. Monocytogenes. Res. J. Pharm. Biol. Chem. Sci. 2015, 6, 625–631.
  54. Alishahi, A. Antibacterial effect of chitosan nanoparticle loaded with nisin for the prolonged effect. J. Food Saf. 2014, 34, 111–118.
  55. Divsalar, E.; Tajik, H.; Moradi, M.; Forough, M.; Lotfi, M.; Kuswandi, B. Characterization of cellulosic paper coated with chitosan-zinc oxide nanocomposite containing nisin and its application in packaging of UF cheese. Int. J. Biol. Macromol. 2018, 109, 1311–1318.
  56. Imran, M.; Klouj, A.; Revol-Junelles, A.M.; Desobry, S. Controlled release of nisin from HPMC, sodium caseinate, poly-lactic acid and chitosan for active packaging applications. J. Food Eng. 2014, 143, 178–185.
  57. Naskar, A.; Kim, K.S. Recent advances in nanomaterial-based wound-healing therapeutics. Pharmaceutics 2020, 12, 499.
  58. Naskar, A.; Lee, S.; Kim, K.-s. Antibacterial potential of Ni-doped zinc oxide nanostructure: Comparatively more effective against Gram-negative bacteria including multidrug resistant strains. RSC Adv. 2020, 10, 1232–1242.
  59. Naskar, A.; Kim, S.; Kim, K.-s. A nontoxic biocompatible nanocomposite comprising black phosphorus with Au–ɣ-Fe2O3 na-noparticles. RSC Adv. 2020, 10, 16162–16167.
  60. Naskar, A.; Lee, S.; Kim, K.-s. Easy one-pot low-temperature synthesized Ag-ZnO nanoparticles and their activity against clinical isolates of methicillin-resistant Staphylococcus aureus. Front. Bioeng. Biotechnol. 2020, 8, 216.
  61. Pandit, R.; Rai, M.; Santos, C.A. Enhanced antimicrobial activity of the food-protecting nisin peptide by bioconjugation with silver nanoparticles. Environ. Chem. Lett. 2017, 15, 443–452.
  62. Preet, S.; Pandey, S.K.; Kaur, K.; Chauhan, S.; Saini, A. Gold nanoparticles assisted co-delivery of nisin and doxorubicin against murine skin cancer. J. Drug Deliv. Sci. Technol. 2019, 53, 101147.
  63. Torres-Martinez, E.J.; Cornejo Bravo, J.M.; Serrano Medina, A.; Pérez González, G.L.; Villarreal Gómez, L.J. A summary of electrospun nanofibers as drug delivery system: Drugs loaded and biopolymers used as matrices. Curr. Drug Deliv. 2018, 15, 1360–1374.
  64. Torres, N.I.; Noll, K.S.; Xu, S.; Li, J.; Huang, Q.; Sinko, P.J.; Wachsman, M.B.; Chikindas, M.L. Safety, formulation, and in vitro antiviral activity of the antimicrobial peptide subtilosin against herpes simplex virus type 1. Probiotics Antimicrob. Pro-teins 2013, 5, 26–35.
  65. Ahire, J.J.; Dicks, L.M. Nisin incorporated with 2,3-Dihydroxybenzoic acid in nanofibers inhibits biofilm formation by a methicillin-resistant strain of Staphylococcus aureus. Probiotics Antimicrob. Proteins. 2015, 7, 52–59.
  66. Niaz, T.; Shabbir, S.; Noor, T.; Imran, M. Antimicrobial and antibiofilm potential of bacteriocin loaded nano-vesicles func-tionalized with rhamnolipids against foodborne pathogens. LWT. 2019, 116, 108583.
  67. Breukink, E.; Ganz, P.; de Kruijff, B.; Seelig, J. Binding of Nisin Z to bilayer vesicles as determined with isothermal titration calorimetry. Biochemistry 2000, 39, 10247–10254.
  68. Yadav, M.K.; Kumar, V.; Singh, B.; Tiwari, S.K. Phospholipid/Polydiacetylene vesicle-based colorimetric assay for high-throughput screening of bacteriocins and halocins. Appl. Biochem. Biotechnol. 2017, 182, 142–154.
  69. Prombutara, P.; Kulwatthanasal, Y.; Supaka, N.; Sramala, I.; Chareonpornwattana, S. Production of nisin-loaded solid lipid nanoparticles for sustained antimicrobial activity. Food Control. 2012, 24, 184–190.
  70. Bi, L.; Yang, L.; Narsimhan, G.; Bhunia, A.K.; Yao, Y. Designing carbohydrate nanoparticles for prolonged efficacy of anti-microbial peptide. J. Control Release 2011, 150, 150–156.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 2.0K
Revisions: 3 times (View History)
Update Date: 11 Oct 2021
Video Production Service